The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCarclo Regulatory News (CAR)

Share Price Information for Carclo (CAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.80
Bid: 12.10
Ask: 13.00
Change: 0.80 (6.81%)
Spread: 0.90 (7.438%)
Open: 12.50
High: 12.50
Low: 11.80
Prev. Close: 11.75
CAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Update on refinancing and current trading

17 Aug 2020 07:00

RNS Number : 2539W
Carclo plc
17 August 2020
 

Carclo plc

 

("Carclo" or "the Group" or "the Company")

 

Update on refinancing and current trading

 

 

Tripartite financing agreement secured

 

The Board announces that on 14 August 2020, the Group agreed revised funding arrangements with the Company's main secured creditors, HSBC and the Pension Scheme, which provide access to ongoing bank facilities as well as visibility over repayment schedules through to July 2023.

 

As part of this agreement, new facilities have been entered into with the Group's lending bank, HSBC, which comprise a Term Loan of £34.5m and a Revolving Credit Facility of £3.5m. In parallel to this, the Group reached agreement with the Trustees of the Pension Scheme in respect of both the actuarial deficit and the resultant deficit repair contributions to be made over the next three years; £2.8m (2021), £3.9m (2022) and £3.8m (2023).

 

As previously announced, securing a suitable long-term funding position for the Group has been a key focus of the Board. With a more stable base now established, the Board can turn its focus to delivering its growth strategy aimed at capturing the significant long-term opportunities it sees for the Group.

 

Update on current trading

 

Group revenue for the continuing businesses for the first quarter was 12% lower than the same period last year. In anticipation of a material reduction in activity in both businesses during the first quarter, the Group implemented a number of operating and commercial initiatives aimed at preserving operational continuity as well as matching cost to reduced demand. The Group has also been able to access Covid-19 relief schemes, particularly in relation to job retention programmes, in a number of its territories including for the UK and US operations. As a result of an effective response by the business, and more resilient demand conditions in certain segments, the overall trading performance in the first quarter of the Group's current financial year to 31 March 2021 was ahead of the Board's initial, Covid-19 adjusted, planning assumptions with both the Technical Plastics and Aerospace divisions recording encouraging performances. Group net debt excluding IFRS16 lease liabilities as at 27 June 2020 was £24.2m (31 March 2020: £22.1m).

 

The Technical Plastics business benefited from robust demand for products relating to Covid-19 testing, which partially offset a reduction in demand for other products in both the medical diagnostics and industrial sectors that had been exacerbated by the impact of government-imposed lockdown of a customer's facility in India. The business was also successful in securing a number of new tooling orders in the medical diagnostics sector which are expected to deliver significant production volumes in future years.

 

The Aerospace Division performed better than anticipated in the first quarter, largely as a result of continued offtake from the existing orderbook, which partly offset the impact of a significant reduction in both newbuild and spares demand from Airbus.

 

Outlook

 

In light of the ongoing uncertainty presented by the pandemic, as well as any wider resultant economic impacts, the Board does not believe that it is possible to provide detailed guidance for the year ending 31 March 2021 at this time. Activity levels in July were broadly in line with those seen in the first quarter and the Board remains cautious about market conditions in the near term. The Group will continue to take action to reduce its cost base, where appropriate, to mitigate the effect of any reduction in demand, whilst seeking to preserve the capability and capacity to respond positively as conditions improve.

 

The Board expects to release the Group's preliminary results on 25 August 2020.

 

Enquiries:

 

FTI Consulting 020 3727 1340

Nick Hasell / Susanne Yule

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDKKABKDBKBAFD
Date   Source Headline
30th Apr 20247:00 amRNSHolding(s) in Company
30th Apr 20247:00 amRNSHolding(s) in Company
26th Apr 20247:00 amRNSTrading Statement
17th Apr 20247:55 amRNSDirectorate Change
15th Apr 20243:55 pmRNSHolding(s) in Company
28th Feb 20247:00 amRNSDirectorate Change
14th Feb 20247:00 amRNSStrategic Consolidation & Tucson Facility Closure
9th Feb 20241:15 pmRNSHolding(s) in Company
29th Jan 202411:09 amRNSDirectorate Change
23rd Jan 20244:48 pmRNSHolding(s) in Company
6th Dec 202310:53 amRNSHolding(s) in Company
30th Nov 20237:00 amRNSHalf-year Report
16th Nov 20237:00 amRNSNotice of Interim Results & Investor Presentation
25th Oct 20233:16 pmRNSCarclo Strategic Decision to Close Derry Facility
22nd Sep 20237:00 amRNSDirector/PDMR Shareholding
31st Aug 20234:01 pmRNSResult of AGM
31st Aug 20237:00 amRNSTrading Update
21st Aug 20231:09 pmRNSDirectorate Change
31st Jul 202311:42 amRNSAnnual Financial Report
18th Jul 20237:00 amRNSBanking covenant update
12th Jul 20237:00 amRNSFinal Results
7th Jul 20237:00 amRNSNotice of Investor Meet Presentation
23rd Jun 20237:00 amRNSBanking covenant adjustment
21st Jun 20231:08 pmRNSNotice of Results
30th May 202310:07 amRNSUpdate on contract cancellation
17th May 20238:46 amRNSHolding(s) in Company
12th May 20239:38 amRNSHolding(s) in Company
14th Apr 20237:00 amRNSTrading Statement
31st Mar 202312:50 pmRNSBanking Covenant update
9th Mar 20239:56 amRNSHolding(s) in Company
24th Feb 20237:00 amRNSDirectorate Change
6th Jan 20234:17 pmRNSHolding(s) in Company
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20221:15 pmRNSDirector/PDMR Shareholding
16th Dec 20221:11 pmRNSDirector/PDMR Shareholding
16th Dec 20221:10 pmRNSDirector/PDMR Shareholding
15th Dec 20227:00 amRNSTrading Update
14th Dec 20224:40 pmRNSSecond Price Monitoring Extn
14th Dec 20224:35 pmRNSPrice Monitoring Extension
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
9th Dec 20227:00 amRNSDirector/PDMR Shareholding
7th Dec 20229:44 amRNSContract Cancellation
6th Dec 20226:29 pmRNSHolding(s) in Company - Replacement
5th Dec 20224:40 pmRNSSecond Price Monitoring Extn
5th Dec 20224:35 pmRNSPrice Monitoring Extension
30th Nov 20227:00 amRNSHalf-year Report
15th Nov 20227:05 amRNSNotice of Interim Results & Investor Presentation
15th Nov 20227:00 amRNSDirectorate Change
7th Nov 20227:00 amRNSBoard Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.